Drugs
TOKYO and SOUTH SAN FRANCISCO, CA: TOKYO and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/06/12 -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Theravance, Inc. (NASDAQ: THRX) today announced that Astellas has exercised its righ ...
CONSHOHOCKEN, PA: CONSHOHOCKEN, PA -- (Marketwire) -- 01/04/12 -- NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseas ...
CARY, NC: CARY, NC -- (Marketwire) -- 01/04/12 -- Cornerstone Therapeutics (NASDAQ: CRTX)Cornerstone acquires worldwide rights to investigational therapy for hyponatremiaHyponatremia is one of the most common ...
BEVERLY, MA: BEVERLY, MA -- (Marketwire) -- 01/03/12 -- Cellceutix Corporation (OTCBB: CTIX) ("the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to t ...
SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/28/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at t ...
WASHINGTON, DC: Newest Members Include Genzyme/Sanofi, Roche, Healthpoint, Life Technologies, Cellular Dynamics, Unite 2 Fight Paralysis, ReNeuron, and TiGenix ...
SAN DIEGO, CA: SAN DIEGO, CA -- (Marketwire) -- 12/19/11 -- Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has initiated the first of four planned Phase 3 clinical trials in its development program ...
VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 12/16/11 -- Sirona Biochem Corp. (TSX VENTURE: SBM) (the "Company"), a biotechnology company specializing in carbohydrate chemistry technolog ...
IRVINE, CA: IRVINE, CA -- (Marketwire) -- 12/16/11 -- ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA)Grossly Inadequate Proposal for $6.50 Per Share Significantly Undervalues ISTAISTA to Host 2012 Guidance and Pipeli ...
FOSTER CITY, CA: FOSTER CITY, CA -- (Marketwire) -- 12/15/11 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the California Superior Court for the County of San Mateo has granted final approval ...
TORONTO, ONTARIO: Development Work Continues on Xylitol Manufacturing Plant Highlights - Nine month product sales increase of 1,149% over prior year to $1.31 million - Gross profit increase of 1,011% during same period ...
PERTH, AUSTRALIA: PERTH, AUSTRALIA -- (Marketwire) -- 12/15/11 -- Phylogica Ltd (ASX: PYC) (XETRA: PH7), a public Australian peptide drug discovery company, announced today the successful completion of the first stag ...
WASHINGTON, DC: Landmark Human Clinical Study Demonstrates Durable Correction of Inherited Bleeding Disorder Using NAV rAAV8 Vectors Encoding Gene for Missing Clotting Factor ...
SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/14/11 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced ...
SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/13/11 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to ...
MONTREAL, CANADA: MONTREAL, CANADA -- (Marketwire) -- 12/12/11 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today the Canadian launch of DigiFab™ Digoxin Immune Fa ...
SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/12/11 -- Theravance, Inc. (NASDAQ: THRX) announced today the initiation of an Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2 study with TD-9855 ...
BOTHELL, WA: New Hire Is Part of Organizational Restructuring Focused on Improving Operational Efficiencies ...
WOODBRIDGE, ONTARIO: WOODBRIDGE, ONTARIO -- (Marketwire) -- 12/05/11 -- Pivotal Therapeutics Inc. (CNSX: PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall healt ...
